Comparison of hospitalization incidence in type B influenza outpatients treated with baloxavir marboxil or oseltamivir phosphate in 2018/2019 and 2019/2020 influenza season using insurance claim database

Comparison of hospitalization incidence in type B influenza outpatients treated with baloxavir marboxil or oseltamivir phosphate in 2018/2019 and 2019/2020 influenza season using insurance claim database - Comparison of hospitalization incidence in type B influenza outpatients treated with baloxavir marboxil or oseltamivir phosphate in 2018/2019 and 2019/2020 influenza season using insurance claim database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051382

Enrollment

15000

Registered

2023-06-20

Start date

2023-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type B Influenza virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Patients with the first diagnosis date of influenza B virus infection during October 1, 2018 to April 17, 2019 or October 1, 2019 to April 17, 2020 and who have 6 months look-back period prior to the diagnosis day (Day 1) 2, Patients who were prescribed baloxavir marboxil or oseltamivir phosphate on Day 1

Exclusion criteria

Exclusion criteria: 1, Prescribed antibacterial agents (ATC middle classification code : J01) on Day 1 2, Diagnosed with pneumonia (ICD-10 code J12-J18) on Day 1 3, Died on Day 1 4, Under 1 year old on Day 1 5, Prescribed multiple anti-influenza drug on Day 1 6, Hospitalized on Day 1

Design outcomes

Primary

Measure	Time frame
Hospitalization incidence (days 2-14) with the date of diagnosis of influenza B virus infection as Day 1	—

Secondary

Measure	Time frame
Incidence of each of the following events from Day 2 to Day 14 -Administration of antibiotic injection -Pneumonia diagnosis -Additional administration of anti-influenza drugs -Administration of antibiotic injection with pneumonia -Oxygen inhalation with pneumonia -Hospitalization with pneumonia -Hospitalization with heart failure -Hospitalization with pneumonia -Hospitalization with heart failure	—

Countries

Japan

Contacts

Public ContactGenta Ito

Shionogi & Co., Ltd. Data Science Department

genta.ito@shionogi.co.jp070-7812-6266

Outcome results